EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules

Marta Banchi, Maria Christina Cox, Guido Bocci

Cancer Letters · 2024

DOI: 10.1016/j.canlet.2024.216900 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2024. Verfasst von Marta Banchi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Administration, Metronomic, Hematologic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metronomic chemotherapy (mCHEMO), based on frequent, regular administration of low, but pharmacologically active drug doses, optimizes antitumor efficacy by targeting multiple targets and reducing toxicity of antineoplastic drugs. This minireview will summarize preclinical and clinical studies on cytotoxic drugs given at weekly, daily, or at continuous metronomic schedules alone or in combination with novel targeted agents for hematological malignancies, including lymphoma, multiple myeloma, and leukemia. Most of the preclinical in vitro and in vivo studies have reported a significant benefit of both mCHEMO monotherapy and combinatorial regimens compared with chemotherapy at the maximum tolerated dose. However, the combination of mCHEMO with targeted drugs is still little explored in the hematologic clinical setting. Data obtained from preclinical studies on low dose metronomic chemotherapy in hematological malignancies clearly suggested the possibility to clinically investigate more tolerable and effective strategies for the treatment of patients with advanced hematological malignancies, or at least for those frail and elderly patients, who are not eligible or resistant to standard treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Administration, MetronomicHematologic NeoplasmsHumansAntineoplastic AgentsAnimalsAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

LeukemiaLymphomaMetronomic chemotherapyMultiple myeloma

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Pisa, Italy.
  • Unità di Ematologia, Fondazione Policlinico Tor Vergata, Rome, Italy.
  • Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Pisa, Italy. Electronic address: guido.bocci@unipi.it.

Zitieren

APA

Banchi, M., Cox, M. C., & Bocci, G. (2024). Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.216900

Vancouver

Banchi M, Cox MC, Bocci G. Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.216900

BibTeX
@article{Banchi2024,
  author = {Banchi, Marta and Cox, Maria Christina and Bocci, Guido},
  title = {Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules},
  journal = {Cancer Letters},
  year = {2024},
  doi = {10.1016/j.canlet.2024.216900}
}
Kostenlos starten →